Diet-induced obesity causes innate airway hyperresponsiveness to methacholine and enhances ozone-induced pulmonary inflammation.
We previously reported that genetically obese mice exhibit innate airway hyperresponsiveness (AHR) and enhanced ozone (O(3))-induced pulmonary inflammation. Such genetic deficiencies in mice are rare in humans, and they may not be representative of human obesity. Thus the purpose of this study was to determine the pulmonary phenotype of mice with diet-induced obesity (DIO), which more closely mimics the cause of human obesity. Therefore, wild-type C57BL/6 mice were reared from the time of weaning until at least 30 wk of age on diets in which either 10 or 60% of the calories are derived from fat in the form of lard. Body mass was approximately 40% greater in mice fed 60 vs. 10% fat diets. Baseline airway responsiveness to intravenous methacholine, measured by forced oscillation, was greater in mice fed 60 vs. 10% fat diets. We also examined lung permeability and inflammation after exposure to room air or O(3) (2 parts/million for 3 h), an asthma trigger. Four hours after the exposure ended, O(3)-induced increases in bronchoalveolar lavage fluid protein, interleukin-6, KC, macrophage inflammatory protein-2, interferon-gamma-inducible protein-10, and eotaxin were greater in mice fed 60 vs. 10% fat diets. Innate AHR and augmented responses to O(3) were not observed in mice raised from weaning until 20-22 wk of age on a 60% fat diet. These results indicate that mice with DIO exhibit innate AHR and enhanced O(3)-induced pulmonary inflammation, similar to genetically obese mice. However, mice with DIO must remain obese for an extended period of time before this pulmonary phenotype is observed.
Johnston
Richard A
RA
Department of Environmental Health, Harvard School of Public Health, Boston , Massachusetts, USA. rajohnst@utmb.edu
Theman
Todd A
TA
Lu
Frank L
FL
Terry
Raya D
RD
Williams
Erin S
ES
Shore
Stephanie A
SA
D000403:Airway Resistance / Q000187:drug effects*; D000818:Animals; D001835:Body Weight; D016535:Bronchial Hyperreactivity / Q000209:etiology* / Q000378:metabolism / Q000503:physiopathology; D001985:Bronchial Provocation Tests; D001992:Bronchoalveolar Lavage Fluid / Q000737:chemistry / Q000166:cytology; D016085:Bronchoconstrictor Agents / Q000008:administration & dosage*; D004041:Dietary Fats / Q000008:administration & dosage; D004195:Disease Models, Animal; D004305:Dose-Response Relationship, Drug; D005260:Female; D018836:Inflammation Mediators / Q000378:metabolism; D007275:Injections, Intravenous; D008170:Lung Compliance; D008297:Male; D016210:Methacholine Chloride / Q000008:administration & dosage*; D051379:Mice; D008810:Mice, Inbred C57BL; D009765:Obesity / Q000150:complications* / Q000209:etiology / Q000378:metabolism / Q000503:physiopathology; D010126:Ozone; D010641:Phenotype; D011014:Pneumonia / Q000139:chemically induced / Q000209:etiology* / Q000378:metabolism / Q000503:physiopathology; D011654:Pulmonary Edema / Q000209:etiology / Q000503:physiopathology; D015656:Respiratory Mechanics
D016085:Bronchoconstrictor Agents; D004041:Dietary Fats; D018836:Inflammation Mediators; D016210:Methacholine Chloride; D010126:Ozone; C029310:lard